Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.1 (
ERK
)
95,504
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BACKGROUND Lung cancer is the most common cause of cancer-associated deaths worldwide. This study aimed to investigate the efficacy and safety of Traditional Chinese Medicine combining
EGFR
-TKIs in treatment of NSCLC patients harboring
EGFR
mutations. MATERIAL AND METHODS This study involved 153 advanced-stage NSCLC patients harboring
EGFR
mutations. Patients were divided into a Control group (administered
EGFR
-TKI, n=61) and an Experimental group (administered Traditional Chinese Medicine combining
EGFR
and TKI, n=92). Progression-free survival (PFS) was evaluated for exon 19 deletion and/or 21 deletion patients. Disease control rate (DCR) was assessed to observe therapeutic effects. Adverse effects, including rashes, diarrhea, ALT/AST increase, dental ulcers, and onychia lateralis, were also evaluated. RESULTS TCM combining
EGFR
-TKI (90.11%) demonstrated no DCR improvement compared to single
EGFR
-TKI (83.33%) (p>0.05). Median PFS (mPFS) of TCM combining
EGFR
-TKI (13 months) was significantly longer compared to that in the single
EGFR
-TKI group (8.8 months) (p=0.001). For 19DEL mutant NSCLC, the mPFS (11 months) in TCM combining
EGFR
-TKI was significantly longer compared to single
EGFR
-TKI (8.5 months) (p=0.007). The mPFS of L858 mutant NSCLC patients in
EGFR
-TKI combining
CTM
(14 months) was significantly longer compared to single
EGFR
-TKI (9.5 months) (p=0.015). TCM combining
EGFR
-TKI was more inclined to prolong mPFS of NSCLC with exon 21 deletion. TCM combining
EGFR
-TKI illustrated no additional adverse effects in NSCLC patients (p=0.956). CONCLUSIONS Application of Traditional Chinese Medicine prolonged progression-free survival and enhanced therapeutic effect in NSCLC patients harboring
EGFR
mutations receiving
EGFR
-TKI treatment. Meanwhile, adjunctive Chinese medicine combining
EGFR
-TKI in NSCLC with
EGFR
mutations caused no adverse effects.
...
PMID:Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations. 3170 7